Kevin Griffiths, MD
Internal Medicine · Washington, DCNPI 1932259702
Payments from drug & device makers
Across 770 payments — averaging $233.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$68K
- Fresenius USA Marketing, Inc.$50K
- Amgen$28K
- Nxstage Medical, Inc.$27K
- AstraZeneca$1K
- Novo Nordisk$798
- plus $5K from 24 others
What the payments were for
- Consulting fees$20,40011%
- Speaking & faculty fees$113,53163%
- Travel & lodging$28,56016%
- Food & beverage$16,6829%
- Education$4270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 126 | $67,523 |
| Fresenius USA Marketing, Inc. | 260 | $50,267 |
| Amgen(2 entities) | 78 | $28,466 |
| Nxstage Medical, Inc. | 37 | $26,664 |
| AstraZeneca(2 entities) | 46 | $1,007 |
| Novo Nordisk | 32 | $798 |
| Bayer | 26 | $606 |
| Novartis | 29 | $594 |
| Akebia Therapeutics Inc | 16 | $465 |
| OPKO Pharmaceuticals, LLC | 18 | $422 |
| Ardelyx, Inc. | 15 | $412 |
| Travere Therapeutics, Inc. | 11 | $403 |
| Aurinia Pharma U.S., Inc. | 12 | $319 |
| Calliditas Therapeutics US Inc. | 8 | $293 |
| Lilly USA, LLC | 11 | $254 |
| Otsuka America Pharmaceutical, Inc. | 11 | $219 |
| Mallinckrodt Enterprises LLC | 5 | $159 |
| Boehringer Ingelheim | 5 | $149 |
| Mallinckrodt Hospital Products Inc. | 4 | $95 |
| GSK | 3 | $80 |
| Vertex | 1 | $73 |
| ANI Pharmaceuticals, Inc. | 2 | $67 |
| Arbor Pharmaceuticals, Inc. | 4 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| Merck | 2 | $42 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Sanofi | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$179,600 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 72 | $147,937 |
| XphozahTenapanor Hcl | 20 | $144,298 |
| FarxigaDapagliflozin Propanediol | 144 | $125,284 |
| JardianceEmpagliflozin | 115 | $113,692 |
| AuryxiaFerric Citrate | 34 | $82,766 |
| RayaldeeCalcifediol | 39 | $62,148 |
| EntrestoSacubitril/Valsartan | 42 | $47,099 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $39,887 |
| OzempicSemaglutide | 15 | $30,807 |
| KerendiaFinerenone | 24 | $29,969 |
| Sevelamer Carbonate | 47 | $24,367 |
| Cinacalcet Hcl | 26 | $22,678 |
| RybelsusSemaglutide | 25 | $18,247 |
| Candesartan Cilexetil | 103 | $5,813 |
| Calcitriol | 172 | $4,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $50,267 | $147,93772 claims |
| AstraZenecaFarxiga | $1,007 | $125,284144 claims |
| Boehringer IngelheimJardiance | $149 | $113,692115 claims |
| Akebia Therapeutics IncAuryxia | $465 | $82,76634 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $422 | $62,14839 claims |
| Novo NordiskOzempic, Rybelsus | $798 | $49,05440 claims |
| NovartisEntresto | $594 | $47,09942 claims |
| BayerKerendia | $606 | $29,96924 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $67 | $1,22540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Federico AschWashington$4.6M
- Geoffrey GibneyWashington$2.3M
- Nnemdi Kamanu EliasWashington$939K
- Andrea SingerWashington$930K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$454K
- Ida BergstromWashington$295K
- Miriam CameronWashington$290K
- Bruce RashbaumWashington$265K
- Maryam Sarraf YazdyWashington$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.